CRISPR

CRISPR2-shank3b

ID
ZDB-CRISPR-190807-2
Name
CRISPR2-shank3b
Previous Names
None
Target
Sequence
5' - GGTGTCCTGAAGAATGATCATGG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
umi102 shank3b
Expression
Gene expression in Wild Types + CRISPR2-shank3b
No data available
Phenotype
Phenotype resulting from CRISPR2-shank3b
No data available
Phenotype of all Fish created by or utilizing CRISPR2-shank3b
Phenotype Fish Conditions Figures
intestinal motility disrupted, abnormal AB + CRISPR11-shank3a + CRISPR2-shank3b standard conditions Fig. 3 with image from James et al., 2019
intestine peristalsis decreased frequency, abnormal AB + CRISPR11-shank3a + CRISPR2-shank3b standard conditions Fig. 3 with image from James et al., 2019
intestinal motility decreased rate, abnormal shank3aumi101/+; shank3bumi102/+ (AB) standard conditions Fig. 4 with image from James et al., 2019
intestine peristalsis decreased frequency, abnormal shank3aumi101/+; shank3bumi102/+ (AB) standard conditions Fig. 3 with image from James et al., 2019
intestine has fewer parts of type enteroendocrine cell, abnormal shank3aumi101/+; shank3bumi102/+ (AB) standard conditions Fig. 7 with image from James et al., 2019
intestinal bulb intestine smooth muscle contraction disrupted, abnormal shank3aumi101/+; shank3bumi102/+ (AB) standard conditions Fig. 4 with image from James et al., 2019
intestinal motility disrupted, abnormal shank3aumi101/+; shank3bumi102/+ (AB) standard conditions Fig. 3 with image from James et al., 2019
intestine has extra parts of type goblet cell, abnormal shank3aumi101/+; shank3bumi102/+ (AB) standard conditions Fig. S2 with image from James et al., 2019
intestine peristalsis decreased frequency, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB) standard conditions Fig. 3 with image from James et al., 2019
intestine has fewer parts of type enteroendocrine cell, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB) standard conditions Fig. 7 with image from James et al., 2019
intestine has extra parts of type goblet cell, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB) standard conditions Fig. S2 with image from James et al., 2019
intestine lumen decreased diameter, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB) standard conditions Fig. S2 with image from James et al., 2019
intestinal motility disrupted, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB) standard conditions Fig. 3 with image from James et al., 2019
intestinal villus swollen, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB) standard conditions Fig. S2 with image from James et al., 2019
swimming behavior process quality, ameliorated shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: risperidone Fig. 3 with image from Kozol et al., 2023
swimming behavior decreased process quality, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) lighting conditions Fig. 1 with imageFig. 3 with imageFig. 4 with imageFig. 5 with imageFig. 6 with image from Kozol et al., 2023
visual behavior decreased process quality, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: lithium chloride Fig. 4 with image from Kozol et al., 2023
visual behavior decreased process quality, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) lighting conditions Fig. 1 with imageFig. 3 with imageFig. 4 with imageFig. 5 with imageFig. 6 with image from Kozol et al., 2023
swimming behavior decreased process quality, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: lithium chloride Fig. 4 with image from Kozol et al., 2023
visual behavior process quality, exacerbated shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: risperidone Fig. 3 with image from Kozol et al., 2023
visual behavior decreased process quality, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: carbamazepine Fig. 5 with image from Kozol et al., 2023
visual behavior process quality, exacerbated shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine Fig. 6 with image from Kozol et al., 2023
swimming behavior process quality, exacerbated shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine Fig. 6 with image from Kozol et al., 2023
swimming behavior decreased process quality, abnormal shank3aumi101/umi101; shank3bumi102/umi102 (AB/TL) chemical treatment by environment: carbamazepine Fig. 5 with image from Kozol et al., 2023
Citations